new glp-1 drugs in development Drugs: 6 Things We've Learned About Their Effects Navigating the -tides: Medication-Assisted Weight

Hepatobiliopancreatic AEs are also discussed in brief because, although they are extremely infrequent, it is important to exercise caution with those patients with a history of pancreatic and gallbladder disorders

In this context, sustained weight-loss interventions, particularly pharmacologic approaches, have become an important therapeutic focus in obesity-related OSAS

[7] Ozempic (semaglutide) [prescribing information]

Nausea, for instance, affects roughly 40.2% to 44.2% of patients but tends to subside as the body adjusts to the medication

Overall, GLP-1 RAs appear to be more efficacious than DPP4 inhibitors in people with type 2 diabetes in terms of improving glycaemic control and reducing body weight (Gilbert and Pratley, 2020)